en · de · es · fr · pt
ipamorelin-notes.peptides6823.com › Blog › �ƒŒ景与受体作用机制 — Hands-On Walkthrough

�ƒŒ景与受体作用机制 — Hands-On Walkthrough

By Editorial Desk · published 2025-12-04 · last reviewed 2026-01-19 · Blog

If you have been reading about pentapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-01-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

背景与受体作用机制

现有文献多来自小规模、短期的研究,涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏,以及重复给药后效应是否衰减,仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大,因此结论外推需谨慎。关于临床获益的确切证据尚不充分,需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Background and Structural Identity

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Ipamorelin at a glance

PropertyValueNotes
分子式C38H49N9O5五肽,含非天然氨基酸残基
分子量711.85 g/mol理论值,盐形式可能略有差异
外观白色至类白色粉末冻干粉常见
溶解性易溶于水也可溶于部分极性有机溶剂
储存条件-20°C,干燥避光长期保存通常推荐

Receptor Mechanism and Secretagogue Action

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Related pages on this site

背景与分子特征

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin Background and Mechanism

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Background and Receptor Selectivity

The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Background from the literature

In early July 2018, then Education Minister, Lisa Thompson, told Queen's Park reporters that starting in September 2018, Ontario schools would no longer be using the sex education curriculum in use since 2015, but would be reverting to the previous curriculum. One of the election campaign promises by the Ford government was to "scrap" the 2015 sex education curriculum. Premier Ford's government said that "it did not order the cancellation." By August 2019, the Ministry of Education, following "widespread consultations," made "only minor tweaks". The "health lesson plan being brought to schools in the fall" of 2019 "is similar to the one Ford crusaded against." On October 11, 2019, Minister Lecce reached a deal with CUPE school support workers, which has to be ratified by CUPE members and averted a pending strike. Premier Ford had said that he would cap "all public sector wage settlements at one per cent per year". The three-year agreement with CUPE was for a "one per cent wage increase annually for the duration of deal." A clause in the agreement clause in the agreement says that if "higher increases are negotiated by other education unions", their union will be able to increase to more than one percent. CUPE also had $58.3 million restored for the "hiring of educational assistants" with an additional $20 million for hiring "more custodians and clerical workers." As well, CUPE's sick leave provisions remained untouched.

Partha Pratim Mitra is an American neuroscientist, computer scientist and entrepreneur. He is the Crick-Clay Professor of Biomathematics at Cold Spring Harbor Laboratory. Mitra holds the H.N. Mahabala Distinguished Chair in Computational Brain Research at IIT Madras and he was a Senior Visiting Researcher at RIKEN, Tokyo, Japan. In 2014, he founded Clarapath, with an aim to automate tissue sectioning in the clinical laboratory.

== Erinacine A == Erinacine A, isolated from the cultured mycelia of Hericium erinaceus, the main representative of this compounds group, has an enhancing effect on nerve growth factor synthesis in vitro. It also increases the levels of catecholamines in the central nervous system of rats.. Erinacine A has been observed to lead to the activation of antioxidant pathways including the transcription factor Nrf2. Stimulator of nerve growth factor (NGF) synthesis in vitro((250.1 ± 36.2) pg/mL at 1.0 mmol/L), weak cytotoxicity against PC12 cells (IC50: 73.7 μmol/L), Anti‐methicillin-resistant Staphylococcus aureus (MRSA) activity Erinacine A has also been prepared by total synthesis.

Relative to 150 mg/day bicalutamide, levels of (R)-bicalutamide are about 15% higher at a dosage of 200 mg/day and about 50% higher at a dosage of 300 mg/day. In contrast to (R)-bicalutamide, the inactive enantiomer (S)-bicalutamide is much more rapidly absorbed (as well as cleared from circulation). Steady-state concentrations of the drug are reached after 4 to 12 weeks of administration independently of dosage, with an approximate 10- to 20-fold progressive accumulation of circulating levels of (R)-bicalutamide. The relatively long time to reach steady-state is a product of the long elimination half-life of bicalutamide. With single 50 mg and 150 mg doses of bicalutamide, mean peak concentrations (Cmax) of (R)-bicalutamide are 0.77 μg/mL (1.8 μmol/L) (at 31 hours) and 1.4 μg/mL (3.3 μmol/L) (at 39 hours), respectively. At steady-state, mean circulating concentrations (Css) of (R)-bicalutamide with 50 mg/day and 150 mg/day bicalutamide are 8.85 μg/mL (20.6 μmol/L) and 21.6 μg/mL (50.2 μmol/L), respectively. In another 150 mg/day bicalutamide study, mean circulating concentrations of (R)-bicalutamide were 19.4 μg/mL (45.1 μmol/L) and 28.5 μg/mL (66.3 μmol/L) on days 28 and 84 (weeks 4 and 12) of treatment, respectively. There is wide interindividual variability, up to 15.7-fold, in steady-state (R)-bicalutamide levels with bicalutamide therapy. This is the case for all dosage levels of bicalutamide, and ranges in (R)-bicalutamide levels for different dosages show significant overlap.

Sources: en.wikipedia.org

Further detail

KFC's core product offering is pressure fried on-the-bone chicken pieces seasoned with Colonel Harland Sanders' "Original Recipe" of 11 herbs and spices. The product is typically available in either two- or three-piece individual servings or in a family size cardboard bucket typically holding between six and 16 chicken pieces. In territories that follow the system handed down by Colonel Sanders, such as Canada and the UK, each chicken is divided into nine different cuts (two drumsticks, two thighs, two wings, two breast pieces and one keel); however, the United States now uses an eight-piece cut. The chicken is hand-breaded at individual KFC outlets with wheat flour mixed with seasoning in a two- to four-minute process. It is then pressure fried for between seven and 10 minutes (the timing differs between countries) in oil at 185 degrees Celsius. Following this, the chicken is left to stand for 5 minutes in order for it to sufficiently cool before it is placed in the warming oven. It is KFC policy to discard chicken if it has not been sold within 90 minutes in order to ensure freshness. The frying oil varies regionally and versions used include sunflower, soybean, rapeseed and palm oil. A KFC executive stated that the taste of the chicken will vary between regions depending on the oil variety used and whether the chicken has been corn-fed or wheat-fed.

=== Bibliography === "Annex A – Estate Baseline – 2009" (PDF). Defence Estates Development Plan (DEDP) 2009. GOV.UK (Report). Ministry of Defence. 3 July 2009. Retrieved 30 March 2023. Halley, James J (1988). RAF Squadrons. The Squadrons of the Royal Air Force & Commonwealth 1918–1988. Tonbridge, UK: Air Britain (Historians). ISBN 0-85130-164-9. Jackson, Paul (1986). Britain's Armed Forces Today: 4 RAF Germany. Shepperton, UK: Ian Allan. ISBN 0-7110-1579-1. Jefford, C. G. (1988). RAF Squadrons. A comprehensive record of the movement and equipment of all RAF squadrons and their antecedents since 1912. Shrewsbury, UK: Airlife. ISBN 1-85310-053-6. Langford, F. (1991). The Dorset Year Book - 1991. Dorset, UK: The Society Of Dorset Men. March, Peter R. (1992). Royal Air Force Yearbook 1992. Fairford, UK: Royal Air Force Benevolent Fund. March, Peter R. (1998). Royal Air Force Yearbook 1998. Fairford, UK: Royal Air Force Benevolent Fund. Sturtivant, Ray; Hamlin, John (2007). Royal Air Force flying training and support units since 1912. Tonbridge, UK: Air-Britain (Historians). ISBN 978-0851-3036-59.

Due to its volatility, short half-life, and high abundance in fission products, 131I (along with the short-lived iodine isotope 132I, which is produced from the decay of 132Te with a half-life of 3 days) is responsible for the most dangerous part of the short-term radioactive contamination after environmental release of the radioactive waste from a nuclear power plant. For that reason, iodine supplements (usually potassium iodide) are given to the populace after nuclear accidents or explosions (and in some cases prior to any such incident as a civil defense mechanism) to reduce the uptake of radioactive iodine compounds by the thyroid.

Pressure-driven operations microfiltration ultrafiltration nanofiltration reverse osmosis gas separation Concentration driven operations dialysis pervaporation forward osmosis artificial lung Operations in an electric potential gradient electrodialysis membrane electrolysis e.g. chloralkaline process electrode ionization electro filtration fuel cell Operations in a temperature gradient membrane distillation

Scores within a BLOSUM are log-odds scores that measure, in an alignment, the logarithm for the ratio of the likelihood of two amino acids appearing with a biological sense and the likelihood of the same amino acids appearing by chance. The matrices are based on the minimum percentage identity of the aligned protein sequence used in calculating them. Every possible identity or substitution is assigned a score based on its observed frequencies in the alignment of related proteins. A positive score is given to the more likely substitutions while a negative score is given to the less likely substitutions. To calculate a BLOSUM matrix, the following equation is used:

Sources: en.wikipedia.org

Frequently asked questions

ipamorelin 是天然存在的肽吗?

不是。它属于人工合成的五肽,设计上模拟胃饥饿素受体的部分作用,但不存在于人体天然激素谱中。

它和生长激素释放激素有何区别?

生长激素释放激素通过其专用受体起作用,而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放,但信号通路和下游效应并不相同。

文献中主要研究哪些方面?

研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限,长期结局尚不明确。

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Network